Mintz Levin Represents Cyclacel Pharmaceuticals Inc. in Sale of Patents to Celgene Corporation For $5.5 Million and Dismissal of All Claims Against Celgene in Patent Litigation Business Wire NEW YORK -- April 5, 2013 Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. represented Cyclacel Pharmaceuticals Inc. in a patent infringement action in which Cyclacel accused Celgene Corporation of infringing four patents related to the use of romidepsin to treat disease. (D.Del. 1:10‐cv‐00348‐GMS). The two companies have filed a joint stipulation and the Court has entered an order dismissing the pending litigation. The parties entered into a definitive agreement with Cyclacel selling the four Cyclacel‐owned patents to Celgene. In connection with the agreement Celgene has made to Cyclacel a one‐time payment of $5.5 million. Cyclacel is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. Representing Cyclacel in the patent litigation agreement were John Bauer, Ivor Elrifi, Marv Gittes and Timur Slomin, Members in the Intellectual Property Practice. Avisheh Avini, an associate in the firm’s Corporate & Securities Practice, also assisted in the agreement. For more information about Mintz Levin, please visit www.mintz.com. Contact: Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. Gina Addis, 617-348-4413 GADDIS@MINTZ.COM
Mintz Levin Represents Cyclacel Pharmaceuticals Inc. in Sale of Patents to Celgene Corporation For $5.5 Million and Dismissal of
Press spacebar to pause and continue. Press esc to stop.